Spanoudakis Emmanouil, Bazdiara Ioanna, Kotsianidis Ioannis, Margaritis Dimitrios, Goutzouvelidis Aggelos, Christoforidou Anna, Tsatalas Costas, Bourikas George
Department of Haematology, Democritus University of Thrace, Medical School, Area of Dragana, Alexandroupolis, Greece.
Ann Hematol. 2009 Jul;88(7):629-32. doi: 10.1007/s00277-008-0650-1. Epub 2008 Dec 19.
Ph-negative chronic myeloproliferative disorders (Ph(neg)cMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases, has not changed their management so far. However, emerging data tend to support a prothrombotic role for the mutation, along with a better response of JAK2V617F mutated patients to hydroxyurea treatment. Our data further support this notion.
Ph 阴性慢性骨髓增殖性疾病（Ph(neg)cMPD）根据估计的血管风险进行治疗。JAK2 激酶 V617F 点突变在这些疾病中频繁出现，但其最近被发现至今尚未改变它们的治疗方式。然而，新出现的数据倾向于支持该突变具有促血栓形成作用，同时 JAK2V617F 突变患者对羟基脲治疗反应更好。我们的数据进一步支持了这一观点。
